Amjad Javed

List of Publications by Year
in descending order

110 papers	9,726 citations	47006 47 h-index	40979 93 g-index
110 all docs	110 docs citations	110 times ranked	9730 citing authors

#	Article	IF	Citations
1	Canonical WNT Signaling Promotes Osteogenesis by Directly Stimulating Runx2 Gene Expression. Journal of Biological Chemistry, 2005, 280, 33132-33140.	3.4	984
2	Oxidative Stress Induces Vascular Calcification through Modulation of the Osteogenic Transcription Factor Runx2 by AKT Signaling. Journal of Biological Chemistry, 2008, 283, 15319-15327.	3.4	533
3	Runx2 control of organization, assembly and activity of the regulatory machinery for skeletal gene expression. Oncogene, 2004, 23, 4315-4329.	5.9	461
4	Networks and hubs for the transcriptional control of osteoblastogenesis. Reviews in Endocrine and Metabolic Disorders, 2006, 7, 1-16.	5.7	397
5	Regulatory Controls for Osteoblast Growth and Differentiation: Role of Runx/Cbfa/AML Factors. Critical Reviews in Eukaryotic Gene Expression, 2004, 14, 1-42.	0.9	392
6	The Runx2 Osteogenic Transcription Factor Regulates Matrix Metalloproteinase 9 in Bone Metastatic Cancer Cells and Controls Cell Invasion. Molecular and Cellular Biology, 2005, 25, 8581-8591.	2.3	280
7	Smooth Muscle Cellâ€"Specific Runx2 Deficiency Inhibits Vascular Calcification. Circulation Research, 2012, 111, 543-552.	4.5	268
8	Dlx3 Transcriptional Regulation of Osteoblast Differentiation: Temporal Recruitment of Msx2, Dlx3, and Dlx5 Homeodomain Proteins to Chromatin of the Osteocalcin Gene. Molecular and Cellular Biology, 2004, 24, 9248-9261.	2.3	261
9	Transient upregulation of CBFA1 in response to bone morphogenetic protein-2 and transforming growth factor ?1 in C2C12 myogenic cells coincides with suppression of the myogenic phenotype but is not sufficient for osteoblast differentiation. Journal of Cellular Biochemistry, 1999, 73, 114-125.	2.6	244
10	Regulatory roles of Runx2 in metastatic tumor and cancer cell interactions with bone. Cancer and Metastasis Reviews, 2006, 25, 589-600.	5.9	236
11	CCAAT/Enhancer-binding Proteins (C/EBP) Î² and Î´ Activate Osteocalcin Gene Transcription and Synergize with Runx2 at the C/EBP Element to Regulate Bone-specific Expression. Journal of Biological Chemistry, 2002, 277, 1316-1323.	3.4	229
12	Mitotic occupancy and lineage-specific transcriptional control of rRNA genes by Runx2. Nature, 2007, 445, 442-446.	27.8	218
13	CbfÎ² interacts with Runx2 and has a critical role in bone development. Nature Genetics, 2002, 32, 639-644.	21.4	207
14	Structural Coupling of Smad and Runx2 for Execution of the BMP2 Osteogenic Signal. Journal of Biological Chemistry, 2008, 283, 8412-8422.	3.4	199
15	Regulatory controls for osteoblast growth and differentiation: role of Runx/Cbfa/AML factors. Critical Reviews in Eukaryotic Gene Expression, 2004, 14, 1-41.	0.9	194
16	Regulation of the Bone-Specific Osteocalcin Gene by p300 Requires Runx2/Cbfa1 and the Vitamin D3 Receptor but Not p300 Intrinsic Histone Acetyltransferase Activity. Molecular and Cellular Biology, 2003, 23, 3339-3351.	2.3	190
17	BMP2 Commitment to the Osteogenic Lineage Involves Activation of Runx2 by DLX3 and a Homeodomain Transcriptional Network. Journal of Biological Chemistry, 2006, 281, 40515-40526.	3.4	188
18	Differential Regulation of the Two Principal Runx2/Cbfa1 N-Terminal Isoforms in Response to Bone Morphogenetic Protein-2 during Development of the Osteoblast Phenotype. Endocrinology, 2001, 142, 4026-4039.	2.8	182

#	Article	IF	Citations
19	Expression and regulation of Runx2/Cbfa1 and osteoblast phenotypic markers during the growth and differentiation of human osteoblasts. Journal of Cellular Biochemistry, 2001, 80, 424-440.	2.6	177
20	Impaired intranuclear trafficking of Runx2 (AML3/CBFA1) transcription factors in breast cancer cells inhibits osteolysis <i>in vivo</i>. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 1454-1459.	7.1	174
21	runt Homology Domain Transcription Factors (Runx, Cbfa, and AML) Mediate Repression of the Bone Sialoprotein Promoter: Evidence for Promoter Context-Dependent Activity of Cbfa Proteins. Molecular and Cellular Biology, 2001, 21, 2891-2905.	2.3	172
22	Osteoblast-related transcription factors Runx2 (Cbfa1/AML3) and MSX2 mediate the expression of bone sialoprotein in human metastatic breast cancer cells. Cancer Research, 2003, 63, 2631-7.	0.9	165
23	A specific targeting signal directs Runx2/Cbfa1 to subnuclear domains and contributes to transactivation of the osteocalcin gene. Journal of Cell Science, 2001, 114, 3093-3102.	2.0	159
24	Mitotic retention of gene expression patterns by the cell fate-determining transcription factor Runx2. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 3189-3194.	7.1	152
25	Nuclear microenvironments in biological control and cancer. Nature Reviews Cancer, 2007, 7, 454-463.	28.4	144
26	Smad function and intranuclear targeting share a Runx2 motif required for osteogenic lineage induction and BMP2 responsive transcription. Journal of Cellular Physiology, 2005, 204, 63-72.	4.1	142
27	Multiple Cbfa/AML Sites in the Rat Osteocalcin Promoter Are Required for Basal and Vitamin D-Responsive Transcription and Contribute to Chromatin Organization. Molecular and Cellular Biology, 1999, 19, 7491-7500.	2.3	141
28	Fidelity of Runx2 Activity in Breast Cancer Cells Is Required for the Generation of Metastases-Associated Osteolytic Disease. Cancer Research, 2004, 64, 4506-4513.	0.9	133
29	Runx2 Regulates Endochondral Ossification Through Control of Chondrocyte Proliferation and Differentiation. Journal of Bone and Mineral Research, 2014, 29, 2653-2665.	2.8	126
30	Functional architecture of the nucleus: organizing the regulatory machinery for gene expression, replication and repair. Trends in Cell Biology, 2003, 13, 584-592.	7.9	121
31	Runx2 Regulates G Protein-coupled Signaling Pathways to Control Growth of Osteoblast Progenitors. Journal of Biological Chemistry, 2008, 283, 27585-27597.	3.4	114
32	The dynamic organization of geneâ€regulatory machinery in nuclear microenvironments. EMBO Reports, 2005, 6, 128-133.	4.5	107
33	Genetic and Transcriptional Control of Bone Formation. Oral and Maxillofacial Surgery Clinics of North America, 2010, 22, 283-293.	1.0	104
34	A Runx2 threshold for the cleidocranial dysplasia phenotype. Human Molecular Genetics, 2008, 18, 556-568.	2.9	97
35	Runx1/AML1 hematopoietic transcription factor contributes to skeletal development in vivo. Journal of Cellular Physiology, 2003, 196, 301-311.	4.1	93
36	Mitotic partitioning and selective reorganization of tissue-specific transcription factors in progeny cells. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 14852-14857.	7.1	88

#	Article	IF	Citations
37	SWI/SNF chromatin remodeling complex is obligatory for BMP2-induced, Runx2-dependent skeletal gene expression that controls osteoblast differentiation. Journal of Cellular Biochemistry, 2005, 94, 720-730.	2.6	84
38	CBFa(AML/PEBP2)-related elements in the TGF-Î² type I receptor promoter and expression with osteoblast differentiation. Journal of Cellular Biochemistry, 1998, 69, 353-363.	2.6	83
39	Transcription factors RUNX1/AML1 and RUNX2/Cbfa1 dynamically associate with stationary subnuclear domains. Journal of Cell Science, 2002, 115, 4167-4176.	2.0	82
40	Biphasic Peptide Amphiphile Nanomatrix Embedded with Hydroxyapatite Nanoparticles for Stimulated Osteoinductive Response. ACS Nano, 2011, 5, 9463-9479.	14.6	78
41	Specific Residues of RUNX2 Are Obligatory for Formation of BMP2-Induced RUNX2-SMAD Complex to Promote Osteoblast Differentiation. Cells Tissues Organs, 2009, 189, 133-137.	2.3	76
42	Reconstitution of Runx2/Cbfa1â€null cells identifies a requirement for BMP2 signaling through a Runx2 functional domain during osteoblast differentiation. Journal of Cellular Biochemistry, 2007, 100, 434-449.	2.6	74
43	Crystal Structure of the Nuclear Matrix Targeting Signal of the Transcription Factor Acute Myelogenous Leukemia-1/Polyoma Enhancer-binding Protein 2Î±B/Core Binding Factor Î±2. Journal of Biological Chemistry, 1999, 274, 33580-33586.	3.4	73
44	Osteogenic differentiation of human mesenchymal stem cells synergistically enhanced by biomimetic peptide amphiphiles combined with conditioned medium. Acta Biomaterialia, 2011, 7, 675-682.	8.3	70
45	Runx2/Cbfa1 Functions: Diverse Regulation of Gene Transcription by Chromatin Remodeling and Co-Regulatory Protein Interactions. Connective Tissue Research, 2003, 44, 141-148.	2.3	56
46	Microtubule-dependent nuclear-cytoplasmic shuttling of Runx2. Journal of Cellular Physiology, 2006, 206, 354-362.	4.1	54
47	Myeloma cellâ€“derived Runx2 promotes myeloma progression in bone. Blood, 2015, 125, 3598-3608.	1.4	52
48	Loss of Runx2 in Committed Osteoblasts Impairs Postnatal Skeletogenesis. Journal of Bone and Mineral Research, 2015, 30, 71-82.	2.8	44
49	Heparanase inhibits osteoblastogenesis and shifts bone marrow progenitor cell fate in myeloma bone disease. Bone, 2013, 57, 10-17.	2.9	43
50	Contributions of nuclear architecture and chromatin to vitamin D-dependent transcriptional control of the rat osteocalcin gene. Steroids, 2001, 66, 159-170.	1.8	41
51	Alterations in intranuclear localization of Runx2 affect biological activity. Journal of Cellular Physiology, 2006, 209, 935-942.	4.1	40
52	Specificity Protein 7 Is Required for Proliferation and Differentiation of Ameloblasts and Odontoblasts. Journal of Bone and Mineral Research, 2018, 33, 1126-1140.	2.8	37
53	The Vitamin D Response Element in the Distal Osteocalcin Promoter Contributes to Chromatin Organization of the Proximal Regulatory Domain. Journal of Biological Chemistry, 2004, 279, 43581-43588.	3.4	36
54	Definitive hematopoiesis requires Runx1 C-terminal-mediated subnuclear targeting and transactivation. Human Molecular Genetics, 2010, 19, 1048-1057.	2.9	35

#	Article	IF	Citations
55	Nuclear microenvironments support assembly and organization of the transcriptional regulatory machinery for cell proliferation and differentiation. Journal of Cellular Biochemistry, 2004, 91, 287-302.	2.6	33
56	Effect of sodium hypochlorite on human pulp cells: an in vitro study. Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics, 2011, 112, 662-666.	1.4	29
57	Angiogenic and Osteogenic Synergy of Human Mesenchymal Stem Cells and Human Umbilical Vein Endothelial Cells Cocultured on a Nanomatrix. Scientific Reports, 2018, 8, 15749.	3.3	29
58	Intranuclear Trafficking: Organization and Assembly of Regulatory Machinery for Combinatorial Biological Control. Journal of Biological Chemistry, 2004, 279, 43363-43366.	3.4	27
59	Organization of transcriptional regulatory machinery in osteoclast nuclei: Compartmentalization of Runx1. Journal of Cellular Physiology, 2005, 204, 871-880.	4.1	26
60	Quantitative signature for architectural organization of regulatory factors using intranuclear informatics. Journal of Cell Science, 2004, 117, 4889-4896.	2.0	25
61	Leukemia-associated AML1/ETO (8;21) chromosomal translocation protein increases the cellular representation of PML bodies. Journal of Cellular Biochemistry, 2000, 79, 103-112.	2.6	22
62	Runx2 activity in committed osteoblasts is not essential for embryonic skeletogenesis. Connective Tissue Research, 2014, 55, 102-106.	2.3	22
63	Transcriptional Auto-Regulation of RUNX1 P1 Promoter. PLoS ONE, 2016, 11, e0149119.	2.5	22
64	Runx2/Cbfa1 Functions: Diverse Regulation of Gene Transcription by Chromatin Remodeling and Co-Regulatory Protein Interactions. Connective Tissue Research, 2003, 44, 141-148.	2.3	22
65	Subnuclear organization and trafficking of regulatory proteins: Implications for biological control and cancer. Journal of Cellular Biochemistry, 2000, 79, 84-92.	2.6	21
66	Organization of transcriptional regulatory machinery in nuclear microenvironments: Implications for biological control and cancer. Advances in Enzyme Regulation, 2007, 47, 242-250.	2.6	21
67	Sp7 and Runx2 molecular complex synergistically regulate expression of target genes. Connective Tissue Research, 2014, 55, 83-87.	2.3	21
68	Subnuclear targeting of Runx1 Is required for synergistic activation of the myeloid specific M-CSF receptor promoter by PU.1. Journal of Cellular Biochemistry, 2005, 96, 795-809.	2.6	20
69	Transcription-factor-mediated epigenetic control of cell fate and lineage commitmentThis paper is one of a selection of papers published in this Special Issue, entitled CSBMCBâ€™s 51st Annual MeetingÂâ€“ Epigenetics and Chromatin Dynamics, and has undergone the Journalâ€™s usual peer review process.. Biochemistry and Cell Biology, 2009, 87, 1-6.	2.0	20
70	Chondrocyte-Specific Regulatory Activity of Runx2 Is Essential for Survival and Skeletal Development. Cells Tissues Organs, 2011, 194, 161-165.	2.3	20
71	Genetic and epigenetic regulation in nuclear microenvironments for biological control in cancer. Journal of Cellular Biochemistry, 2008, 104, 2016-2026.	2.6	18
72	Runx2 Deficiency in Osteoblasts Promotes Myeloma Progression by Altering the Bone Microenvironment at New Bone Sites. Cancer Research, 2020, 80, 1036-1048.	0.9	18

#	Article	IF	Citations
73	Heparanase promotes myeloma progression by inducing mesenchymal features and motility of myeloma cells. Oncotarget, 2016, 7, 11299-11309.	1.8	15
74	Runx2 is required for hypertrophic chondrocyte mediated degradation of cartilage matrix during endochondral ossification. Matrix Biology Plus, 2021, 12, 100088.	3.5	15
75	MicroRNA 665 Regulates Dentinogenesis through MicroRNA-Mediated Silencing and Epigenetic Mechanisms. Molecular and Cellular Biology, 2015, 35, 3116-3130.	2.3	14
76	Intranuclear organization of RUNX transcriptional regulatory machinery in biological control of skeletogenesis and cancer. Blood Cells, Molecules, and Diseases, 2003, 30, 170-176.	1.4	13
77	Dwarfism in homozygous Agc1^{CreERT} mice is associated with decreased expression of aggrecan. Genesis, 2017, 55, e23070.	1.6	13
78	Altered chromatin modifications in <i>AML1/RUNX1</i> breakpoint regions involved in (8;21) translocation. Journal of Cellular Physiology, 2009, 218, 343-349.	4.1	12
79	Combinatorial organization of the transcriptional regulatory machinery in biological control and cancer. Advances in Enzyme Regulation, 2005, 45, 136-154.	2.6	9
80	Runx2 Regulates the Gene Network Associated with Insulin Signaling and Energy Homeostasis. Cells Tissues Organs, 2011, 194, 232-237.	2.3	8
81	Insight into Regulatory Factor Targeting to Transcriptionally Active Subnuclear Sites. Experimental Cell Research, 1999, 253, 110-116.	2.6	6
82	Nuclear microenvironments support physiological control of gene expression. Chromosome Research, 2003, 11, 527-536.	2.2	6
83	Disruption of the preB Cell Receptor Complex Leads to Decreased Bone Mass. Frontiers in Immunology, 2019, 10, 2063.	4.8	6
84	Dentin and Bone: Similar Collagenous Mineralized Tissues. , 2010, , 183-200.		6
85	Runx2 Deficiency in Osteoblasts Promotes Myeloma Resistance to Bortezomib by Increasing TSP-1â€"Dependent TGFÎ²1 Activation and Suppressing Immunity in Bone Marrow. Molecular Cancer Therapeutics, 2022, 21, 347-358.	4.1	6
86	<I>In Situ</I> Immunofluorescence Analysis: Immunofluorescence Microscopy. , 2004, 285, 023-028.		5
87	Organization, Integration, and Assembly of Genetic and Epigenetic Regulatory Machinery in Nuclear Microenvironments. Annals of the New York Academy of Sciences, 2009, 1155, 4-14.	3.8	5
88	Chromatin Immunoprecipitation Assays: Application of ChIP-on-Chip for Defining Dynamic Transcriptional Mechanisms in Bone Cells. Methods in Molecular Biology, 2008, 455, 165-176.	0.9	5
89	Subnuclear Localization and Intranuclear Trafficking of Transcription Factors. Methods in Molecular Biology, 2010, 647, 77-93.	0.9	4
90	Epigenetic remodeling and modification to preserve skeletogenesis in vivo. Connective Tissue Research, 2018, 59, 52-54.	2.3	4

#	Article	IF	Citations
91	Involvement of Nuclear Architecture in Regulating Gene Expression in Bone Cells. , 2002, , 169-XVII.		4
92	Proteinâ€"Deoxyribonucleic Acid Interactions Linked to Gene Expression: Electrophoretic Mobility Shift Assay. , 2004, 285, 045-056.		3
93	Specificity protein 7 is not essential for tooth morphogenesis. Connective Tissue Research, 2014, 55, 88-91.	2.3	3
94	Subnuclear organization and trafficking of regulatory proteins: Implications for biological control and cancer. Journal of Cellular Biochemistry, 2000, 79, 84-92.	2.6	3
95	Intranuclear trafficking of transcription factors: Requirements for vitamin D-mediated biological control of gene expression. Journal of Cellular Biochemistry, 2003, 88, 340-355.	2.6	2
96	<I>In Situ</I> Immunofluorescence Analysis: Analyzing RNA Synthesis by 5-Bromouridine-5'-Triphosphate Labeling. , 2004, 285, 029-032.		2
97	Chromatin Immunoprecipitation. , 2004, 285, 041-044.		2
98	Breakpoint regions ofETOgene involved in (8; 21) leukemic translocations are enriched in acetylated histone H3. Journal of Cellular Biochemistry, 2013, 114, 2569-2576.	2.6	2
99	Expression and regulation of Runx2/Cbfa1 and osteoblast phenotypic markers during the growth and differentiation of human osteoblasts*. , 2001, 80, 424.		2
100	Intranuclear Organization of the Regulatory Machinery for Vitamin Dâ€"Mediated Control of Skeletal Gene Expression. , 2005, , 327-340.		2
101	Immunofluorescence Analysis Using Epitope-Tagged Proteins: In Vitro System. , 2004, 285, 033-036.		1
102	Runx2 Transcription Factor Regulates Heparanase-Induced Bone Resorption in Multiple Myeloma. Blood, 2012, 120, 567-567.	1.4	1
103	Myeloma Cell-Derived Runx2 Promotes Myeloma Progression and Bone-Homing. Blood, 2014, 124, 724-724.	1.4	1
104	Proteinâ€"Deoxyribonucleic Acid Interactions Linked to Gene Expression: DNase I Digestion. , 2004, 285, 057-062.		0
105	Proteinâ€"Deoxyribonucleic Acid Interactions Linked to Gene Expression: Ligation-Mediated Polymerase Chain Reaction. , 2004, 285, 063-068.		0
106	Analysis of In Vivo Gene Expression Using Epitope-Tagged Proteins. , 2004, 285, 037-040.		0
107	Skeletal Gene Expression in Nuclear Microenvironments. , 2008, , 263-283.		0
108	In Situ Nuclear Organization of Regulatory Machinery. Methods in Molecular Biology, 2008, 455, 239-259.	0.9	0

#	Article	IF	Citations
109	Identification of Potential Enhancers in the RUNX1 Gene. FASEB Journal, 2009, 23, 489.1.	0.5	0
110	Runx2 Deficiency in Osteoblasts Promotes Myeloma Resistance to Bortezomib By Increasing TSP-1-Dependent TGF-Î²1 Activation in Bone Marrow. Blood, 2021, 138, 1575-1575.	1.4	0